3-chloro-4,6-dimethylpyridin-2(1H)-one | 1354528-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-chloro-4,6-dimethylpyridin-2(1H)-one
• 英文别名: 3-Chloro-4,6-dimethyl-1,2-dihydropyridin-2-one；3-chloro-4,6-dimethyl-1H-pyridin-2-one
• CAS: 1354528-17-8
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: VVOLQHWZWJMPAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chloro-4,6-dimethylpyridin-2(1H)-one 在 potassium phosphate 、 甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(II) 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 2.25h， 生成 methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(8-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)chroman-5-yl)propanoate
  参考文献：
  名称：

  [EN] COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN
  [FR] COMPOSÉS POUR L'INHIBITION DE L'INTÉGRINE ALPHA 4 BÊTA 7

  摘要：

  本公开提供一种如下式（I）的化合物或其药用可接受的盐。本公开还提供包括如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，以及治疗炎症性疾病的治疗方法。

  公开号：

  WO2020092383A1

文献信息

• [EN] COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN<br/>[FR] COMPOSÉS POUR INHIBITION DE L'INTÉGRINE ALPHA 4β7
  申请人：GILEAD SCIENCES INC

  公开号：WO2020092401A1

  公开（公告）日：2020-05-07

  The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供一种如下所述的化合物的化学式(I)；或其药用可接受的盐。本公开还提供包括化合物的药物组合物的制备方法，制备化合物的方法和治疗炎症性疾病的治疗方法。
• Compounds for inhibition of α4β7 integrin
  申请人：Gilead Sciences, Inc.

  公开号：US11179383B2

  公开（公告）日：2021-11-23

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。
• Compounds for inhibition of alpha 4 beta 7 integrin
  申请人：Gilead Sciences, Inc.

  公开号：US11224600B2

  公开（公告）日：2022-01-18

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。
• COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN
  申请人：Gilead Sciences, Inc.

  公开号：US20200155563A1

  公开（公告）日：2020-05-21

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
• Compounds for Inhibition of Alpha 4 Beta 7 Integrin
  申请人：Gilead Sciences, Inc.

  公开号：US20200163953A1

  公开（公告）日：2020-05-28

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.